Around the year 2000, pharmaceutical company Merck launched the drug Vioxx. A painkiller that quickly became popular and just as quickly proved dangerous. The company knew even before Vioxx was produced for patients that using this drug significantly increased the risk of heart and brain attacks. But it didn't warn about that. Not in the package insert and not to the authorities who had to approve Vioxx.
In 2004, Merck took Vioxx off the market worldwide. It was one of the largest recalls in pharmaceutical history. Our clients had already suffered infarctions by then.
Victims in the Netherlands, settlements in America
We performed for a large group of Dutch victims. People who had taken Vioxx and then suffered an infarction. Some were left with permanent health damage.
In America, Merck reached settlements with injured parties. In the Netherlands, the company did not want to come to the table. Merck made it public that it would not settle because of Vioxx. Outside America, they did so in few countries.
We continued.
Thousands of binders, one decisive piece of evidence
There were two crucial things to prove. First: that the infarction had been caused by Vioxx, and not some other cause. Second: that Merck knew about the increased risk before the market launch.
Through the courts, we demanded Merck's internal research documents. In a room we searched through thousands of binders for what was not in the package insert. Finally, we found the reports from the research phase, prepared before Vioxx came on the market. These showed that Merck knew the drug worryingly increased the risk of infarction. The company had not shared that information with regulators.
The road to the negotiating table
To establish Merck's liability judicially as a basis for settlement, we selected several clients from the group as litigators. Their cases were a model for the rest.
The decisive step toward Merck was taken by a lawyer from our international network. Without that opening, the negotiations would not have got off the ground. This shows the importance of international contacts in cases with a foreign counterparty.
Retrospective
“That the perseverer wins certainly applies to this case,” says Christa Wijnakker. “Merck had made it public that they would not settle because of Vioxx, and have done so in few countries outside America. It hit me that Vioxx was taken off the market in 2004 because of the risk of infarction, and the failure to warn about it. And that Merck did not want to take responsibility towards Dutch victims for a long time after that.”
Do you have questions about this case? Please contact Christa Wijnakker.





